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Abstract
Tumor hypoxia is a major cause of treatment failure for a variety of malignan-
cies. However, hypoxia offers treatment opportunities, exemplified by the de-
velopment of compounds that target hypoxic regions within tumors. Evofosfamide 
(TH- 302) is a prodrug created by the conjugation of 2- nitroimidazole to bromo- 
isophosphoramide mustard (Br- IPM). When evofosfamide is delivered to hypoxic 
regions, the DNA cross- linking effector, Br- IPM, is released. This study assessed 
the cytotoxic activity of evofosfamide in vitro and its antitumor activity against 
osteolytic breast cancer either alone or in combination with paclitaxel in vivo. 
A panel of human breast cancer cell lines were treated with evofosfamide under 
hypoxia and assessed for cell viability. Osteolytic MDA- MB- 231- TXSA cells were 
transplanted into the mammary fat pad, or into tibiae of mice, allowed to 
establish and treated with evofosfamide, paclitaxel, or both. Tumor burden was 
monitored using bioluminescence, and cancer- induced bone destruction was 
measured using micro- CT. In vitro, evofosfamide was selectively cytotoxic under 
hypoxic conditions. In vivo evofosfamide was tumor suppressive as a single 
agent and cooperated with paclitaxel to reduce mammary tumor growth. Breast 
cancer cells transplanted into the tibiae of mice developed osteolytic lesions. In 
contrast, treatment with evofosfamide or paclitaxel resulted in a significant delay 
in tumor growth and an overall reduction in tumor burden in bone, whereas 
combined treatment resulted in a significantly greater reduction in tumor burden 
in the tibia of mice. Evofosfamide cooperates with paclitaxel and exhibits potent 
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Introduction
Breast cancer is the most common cancer and the leading 
cause of cancer mortality in women worldwide [1]. Bone 
metastasis occurs in over 75% of patients with breast 
cancer and is associated with extensive bone destruction, 
leading to pathological fractures, bone pain, spinal cord 
compressions, and hypercalcemia [2]. While much progress 
has been made in the diagnosis and treatment of primary 
disease, metastatic breast cancer remains a challenging 
condition to treat and patients with advanced disease 
continue to die due to metastatic burden. Therefore, there 
is a great need to identify more effective anticancer thera-
peutics to improve patients’ disease- free survival, especially 
in patients with advanced or metastatic disease.
Solid tumors, including breast cancer, are less well- 
oxygenated than the normal tissues from which they arise. 
This so- called tumor hypoxia is described by a significant 
portion of the tumor mass, usually the center of the 
tumor, becoming less oxygenated due to its long distance 
from blood vessels and the slower rate of proliferation 
of the cancer cells in that area [3, 4]. This makes cancer 
cells residing in the hypoxic regions most likely to be 
resistant to chemotherapy and radiotherapy which then 
allows the tumor to recur and metastasize. Hence, tumor 
hypoxia is a major cause of treatment failure, poor out-
comes, and recurrence for a variety of malignancies.
These low oxygen levels found in tumor subregions 
are rarely observed in normal tissues. Tumor hypoxia can 
therefore serve as the basis for selective cancer therapy, 
and there are a variety of therapeutic strategies being 
pursued for the selective targeting of hypoxic tumor cells. 
Hypoxia- activated prodrugs (HAPs) are exciting new thera-
peutics that enable the selective delivery of cytotoxic or 
cytostatic agents to hypoxic tumor cells. Evofosfamide 
(formally known as TH- 302) is a HAP composed of 
2- nitroimidazole conjugated to bromo- isophosphoramide 
mustard (Br- IPM) [5]. The 2- nitroimidazole component 
of evofosfamide acts as an oxygen sensor, causing evo-
fosfamide to fragment in a one electron reductase- 
dependent process selectively under hypoxic conditions, 
releasing the bisalkylating effector, bromo- 
isophosphoramide (Br- IPM) which is a potent alkylating 
agent creating DNA cross- links. The DNA damage is 
recognized by the DNA damage response (DDR). The 
variant histone H2AX is phosphorylated, producing γH2AX 
and activating Chk1 and cell cycle arrest [6]. In addition, 
recent studies have shown that under hypoxic conditions, 
evofosfamide causes the inactivation of thioredoxin reduc-
tase [7], which regulates several cellular processes including 
the protection from damage caused by reactive oxidant 
species (ROS) and apoptosis by the apoptosis signal- 
regulating kinase 1 enzyme (ASK- 1) [8].
Evofosfamide is currently in various stages of clinical 
trials, due to its efficacy against numerous cancer types 
including pancreatic cancer, multiple myeloma, soft- tissue 
sarcoma, and melanoma [9, 10]. However, to date, there 
has been no investigation looking at the anticancer efficacy 
of evofosfamide for the treatment of breast cancer at the 
primary site and, in particular, its growth in bone. It 
must be noted that the bone marrow itself is hypoxic, 
when compared with other tissues and metastatic cancer 
cells such as breast cancer cells, preferentially seed in 
these hypoxic niches [11]. Unlike soft- tissue tumors, cancer 
cells in bone adapt to survive in this hypoxic bone 
microenvironment.
Therefore, the ability to target bone metastases in this 
hypoxic environment is an important advantage that evo-
fosfamide has over other cancer treatments. Taking this 
into consideration and the fact that conventional chemo-
therapeutics are usually cytotoxic to normal cells in the 
bone marrow, combination of chemotherapeutic agents 
with evofosfamide should reduce toxicity to these bone 
cells, especially since we have recently shown evofosfamide 
to be nontoxic to normal bone cells [12]. This study 
assessed the cytotoxic activity of evofosfamide against a 
panel of human breast cancer cell lines in vitro and evalu-
ated its antitumor efficacy alone and in combination with 
the chemotherapeutic agent paclitaxel in vivo, using animal 
models of osteolytic breast cancer.
Materials and Methods
Cells
The human breast cancer cell lines MDA- MB- 468, MDA- 
MB- 453, MCF- 7, T47D, and ZR- 75 and the breast epithelial 
cell lines MCF- 10A and MCF- 12A were obtained from 
ATCC (Manassas, VA). The MDA- MB- 231 derivative cell 
line, MDA- MB- 231- TXSA, was kindly provided by Dr. 
Toshiyuki Yoneda (formerly at University of Texas Health 
Sciences Centre, San Antonio, TX). The generation of 
luciferase- tagged MDA- MB- 231- TXSA- TGL was described 
previously [13]. Normal mammary fibroblast cells were 
provided by Wendy Ingman (University of Adelaide, 
Australia), and the dermal fibroblasts were a gift from 
John E.Greenwood (Adult Burn Centre, Royal Adelaide 
Hospital, Australia). The breast cancer lines and fibroblasts 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 2 mmol/L glutamine, 
100 IU/mL penicillin, 160 μg/mL gentamicin, and 10% 
fetal bovine serum (Life Technologies, Carlsbad, CA). The 
epithelial cell lines were cultured in membrane epithelial 
basal media (Lonza, Basel, Switzerland) containing 10% 
fetal bovine serum. All cell lines were maintained in a 
5% CO2- containing humidified atmosphere.
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Drugs
Evofosfamide was provided by Threshold Pharmaceuticals 
(South San Francisco, CA) and dissolved in sterile saline 
at a concentration of 13.2 mmol/L. The ZVAD- fmk 
(Caspase Inhibitor- 1) was purchased from Calbiochem 
(Inc. La Jolla, CA), and Paclitaxel was purchased from 
Ebewe Pharma (A- 4866; Unterach, Austria).
Cell viability assay
To determine the cytotoxic effects of evofosfamide on 
cell growth, 1 × 104 cells per well were seeded in 96- well 
microtiter plates and allowed to adhere overnight. Cells 
were then treated with increasing concentrations of evo-
fosfamide (1–50 μmol/L) for 48 h as shown in Figure 1A 
or 24 h (1–100 μmol/L) as shown in Figure 1B, under 
normoxic and various hypoxic conditions. Cell viability 
was determined by crystal violet staining, and optical 
density was measured at 570- nm wavelength (OD570). 
Experiments were performed in triplicate and repeated at 
least 3 times. Results of representative experiments are 
presented as the mean ± SD.
Apoptosis analysis
DAPI staining of nuclei
Cells were seeded on plastic chamber slides and treated 
at 1% O2 with evofosfamide at 50 μmol/L for 24 h. After 
two washes with PBS, cells were fixed in ethanol:acetic 
acid (6:1) for 10 min, washed again with PBS, and incu-
bated with 0.8 mg/mL of 4′,6- diamidine- 2′- phenylindole 
dihydrochloride (DAPI; Roche Diagnostics, Mannheim, 
Germany) in methanol for 15 min. After several washes 
in PBS, the coverslips were mounted on ProLong®Gold 
antifade (Life Technologies). DAPI staining was visualized 
by fluorescence microscopy.
Measurement of DEVD- caspase activity
DEVD- caspase activity was assayed by cleavage of zDEVD- 
AFC, a fluorogenic substrate based on the peptide sequence 
at the caspase- 3 cleavage site of poly (ADP- ribose) poly-
merase. Cells (1 × 104/well) grown in 96- well plates were 
treated as indicated, washed once with PBS, and resus-
pended in 30 μL lysis buffer containing 5 mmol/L Tris- 
HCl, 5 mmol/L EDTA, and 10% Igepal (pH 7.5). Cell 
lysate (15–20 μg of protein) was added to each assay 
tube containing 8 μmol/L substrate in 1 mL fluorometric 
protease buffer (50 mmol/L HEPES, 10% sucrose, 
10 mmol/L DTT, 0.1% CHAPS [pH 7.4]). After 4–5 h 
at room temperature, fluorescence was quantified (Ex 400 
and Em 505) in a Perkin- Elmer LS50 fluorescence 
spectrometer. Results were expressed relative to the protein 
concentration of the sample and determined using a com-
mercial BCA protein assay reagent from Thermo Fisher 
Scientific (Waltham, MA).
Western blot analysis
Cells were treated with evofosfamide at 50 μmol/L in a 
time- dependent manner (0, 6, 12, 24, 48 h) under nor-
moxic (21% O2) and hypoxic (1% O2) conditions and 
lysed in buffer containing 10 mmol/L Tris- HCl, pH 7.6, 
150 mmol/L NaCl, 1% Triton X- 100, 0.1% sodium dodecyl 
sulfate (SDS), 2 mmol/L sodium vanadate, and a protease 
inhibitor cocktail (Roche Diagnostics). Protein lysates were 
heated at 70°C for 10 min and loaded into 4–12% poly-
acrylamide gels for electrophoresis under reducing condi-
tions. Separated proteins were electrophoretically 
transferred to PVDF membranes (GE Healthcare, 
Buckinghamshire, UK) and blocked in PBS containing 
5% blocking reagent (GE Healthcare) for 1 h at room 
temperature.
Immunodetection was performed overnight at 4°C in 
PBS/blocking reagent containing 0.1% Tween 20, using 
the following primary antibodies at the dilutions suggested 
by the manufacturer. mAb anticaspase- 8, mAb anticaspase-
 3, pAb antibid, pAb anticaspase- 9, pAb PI3 kinase Class 
III, pAb phospho- p44/42 MAPK, pAb p44/42 MAPK, pAb 
phospho- Akt, and pAb Akt were purchased from Cell 
Signaling Technology (Beverly, MA), pAb anti- inhibitor 
of apoptosis 1 (cIAP1), pAb anti- inhibitor of apoptosis 
2 (cIAP2), pAb anti- XIAP from R&D  systems, pAb anti- 
BAX, pAb anti- p53, pAb anti- p21, and mAb anti- Bcl- 2 
were purchased from Santa Cruz Biotechnology (Dallas, 
Texas) and pAb anti- poly- (ADP- Ribose) polymerase 
(PARP) from Roche Diagnostics. Anti- actin mAb (Sigma, 
Saint Louis, MO) was used as a  loading control. Membranes 
were then rinsed several times with PBS containing 0.1% 
Tween- 20 and incubated with 1:5000 dilution of anti- 
mouse, anti- goat, or anti- rabbit alkaline phosphatase- 
conjugated secondary antibodies (Thermo Fisher Scientific) 
for 1 h. Visualization and quantification of protein bands 
was performed using the ECF substrate reagent kit (GE 
Healthcare) on a FluorImager (Molecular Dynamics Inc., 
Sunnyvale, CA).
Animals
Female athymic mice at 5 weeks old (Institute of Medical 
and Veterinary Services Division, Gilles Plains, SA, Australia) 
were acclimatized to the animal housing facility for a 
minimum period of 1 week prior to the commencement 
of experimentation. The general physical well- being and 
weight of animals were monitored continuously throughout 
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Figure 1. Activity of evofosfamide against breast cancer, epithelial cells, and fibroblasts in vitro. (A) Six breast cancer cell lines were seeded in 96- well 
plates at 1 × 104 cells per well and treated with increasing doses of evofosfamide in normoxic (21% O2) and hypoxic (1% O2) conditions for 48 h. (B) 
The breast cancer cell line MDA- MB- 231- TXSA was treated with an increasing dose of evofosfamide under normoxic (21% O2) and in various hypoxic 
conditions from 0% to 5% O2 for 24 h. (C) Evofosfamide reduced cell viability in both epithelial breast cell lines MCF- 10A and MCF- 12A selectively 
under hypoxic conditions (1% O2) 48 h after treatment. Dermal and mammary fibroblasts were relatively resistant to evofosfamide under the same 
conditions. Cell viability of all cell lines was assessed by crystal violet staining. (D) DAPI nuclear fluorescence stain of untreated MDA- MB- 231- TXSA 
cells showing nuclei homogenously stained. Cells treated with 50 μmol/L evofosfamide under hypoxic conditions for 24 h exhibit changes in the nuclei 
consistent with the induction of apoptosis. Data points show means of quadruplicate results from a representative experiment, repeated at least twice 
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the experiments. All mice were housed under pathogen- 
free conditions, and all experimental procedures on animals 
were carried out with strict adherence to the rules and 
guidelines for the ethical use of animals in research and 
were approved by the Animal Ethics Committees of the 
University of Adelaide and the Institute of Medical and 
Veterinary Science, Adelaide, SA, Australia.
Mammary fat pad injections of breast 
cancer cells
MDA- MB- 231- TXSA- TGL human breast cancer cells were 
cultured as described above until they reached 70–80% 
confluency. Cells were removed from flasks with 2 mmol/L 
EDTA and resuspended in 1 × PBS at 1 × 105 cells/10 μL 
and kept on ice in an eppendorf tube. An equal volume 
of Matrigel™- HC (BD Biosciences, Bedford, MA) was added 
to the cells and resuspended. The mice were anesthetized 
by Isoflurane (Faulding Pharmaceuticals, SA, Australia), 
the mammary fat pad area of the mice was wiped with 
ethanol, and the skin was lifted over the left outermost 
nipple. Finally, 20 μL of cells was injected into the mam-
mary fat pad using a 25- gauge needle, and animals were 
allowed to recover under a heat lamp before being trans-
ferred into cages. Mice were then assigned randomly into 
groups of 10 animals each. Evofosfamide was given via 
intraperitoneal injection at a dose of 50 mg/kg once a 
day for 5 consecutive days, followed by 2 days rest. 
Paclitaxel was given at a dose of 6.25 mg/kg subcutane-
ously once a week. The dosing started 7 days after cancer 
cell implantation and was given every week until the end 
of the experiment, at day 21.
Intratibial injections of breast cancer cells
MDA- MB- 231- TXSA- TGL cells were cultured as described 
above. The left tibia was wiped with 70% ethanol, and 
a 27- gauge needle coupled to a Hamilton syringe was 
inserted through the tibial plateau with the knee flexed; 
1 × 105 MDA- MB- 231- TXSA- TGL cells resuspended in 
10 μL of PBS were then injected in the marrow space. 
All animals were injected with PBS in the contralateral 
tibia as the control. Mice were then assigned randomly 
into groups of 10 animals per group and received the 
same treatments described in the mammary fat pad 
model.
In vivo bioluminescent imaging
Noninvasive, whole- body imaging to monitor luciferase- 
expressing MDA- MB- 231- TXSA- TGL cells in mice was 
performed weekly using the IVIS 100 Imaging system 
(Xenogen, Alameda, CA). Mice were injected i.p. with 
100 μL of the d- Luciferin solution at final dose of 
3 mg/20 g mouse body weight (Xenogen) and then gas 
anesthetized with Isoflurane (Faulding Pharmaceuticals). 
Images were acquired for 0.5–30 sec (representative images 
are shown at 1 sec), and the photon emission transmit-
ted from mice was captured and quantitated in photons/
sec/cm2/sr using Xenogen Living image (Igor Pro version 
2.5) software.
Microcomputed tomography ex vivo 
analysis
Limbs for μCT analysis were surgically resected and scanned 
using the SkyScan- 1072 high- resolution μCT Scanner 
(Skyscan, Kontich, Belgium). The Scanner was operated 
at 80 kV, 120 μA, rotation step 0.675, 0.5 mm Al filter 
and scan resolution of 5.2 μm/pixel. The cross- sections 
were reconstructed using a cone- beam algorithm (software 
Cone rec, Skyscan). Using the 2D images obtained from 
the μCT scan, the growth plate was identified and 400 
sections were selected starting from the growth plate/tibial 
interface and moving down the tibia. For quantification, 
3D evaluation was performed on all data sets acquired 
by selecting total bone of the proximal tibia, to determine 
3D bone morphometric parameters (software CTAn, 
Skyscan). The cross- sections were reconstructed using a 
cone- beam algorithm (software Cone_rec, Skyscan). Files 
were then imported into CTAn software (Skyscan) for 3D 
analysis and 3D image generation. All images are viewed 
and edited using ANT visualization software (Skyscan).
Histology
Tibiae were fixed in 10% (v/v) buffered formalin (24 h 
at 4°C), followed by 2 weeks of decalcification in 0.5 mol/L 
EDTA/0.5% paraformaldehyde in PBS, pH 8.0 at 4°C. 
Complete decalcification was confirmed by radiography 
and tibiae were then paraffin embedded. Five- micron 
longitudinal sections were prepared and stained with H&E. 
Analysis was performed using the Nanozoomer and the 
Hamamatsu software.
Data analysis and statistics
Experiments were performed in triplicate, and data pre-
sented as mean ± SE. All statistical analysis was performed 
using SigmaStat for Windows version 3.0 (Systat Software, 
Inc., Port Richmond, CA) using the unpaired Students’ 
t-test. Measures of association between two variables were 
assessed using the Spearman’s rank correlation coefficient. 
Comparisons between groups were assessed using a one- 
way analysis of variance test. In all cases, P < 0.05 was 
considered statistically significant.
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Results
Evofosfamide exhibits hypoxia- selective 
cytotoxicity on human breast cancer cells
A panel of human breast cancer cell lines (MDA- MB- 
231- TXSA, MDA- MB- 453, MDA- MB- 468, ZR- 75, MCF- 7, 
and T47D) were assessed for their sensitivity to the cyto-
toxic effects of evofosfamide under normoxic (21% O2) 
and hypoxic (1% O2) conditions. Evofosfamide exhibited 
relatively minimal toxicity under normoxic conditions, 
whereas under hypoxic conditions (1% O2), evofosfamide 
reduced cell viability in a dose- dependent manner after 
48 h of treatment, with IC50 values ranging between 1 
and 25 μmol/L and a maximum of 50–90% loss of viability 
at the highest dose of 50 μmol/L (Fig. 1A). The hypoxia 
selectivity of evofosfamide, in the MDA- MB- 231- TXSA 
cells measured as a ratio of IC50 values under varying 
conditions of hypoxia (0%, 0.5%, 1.0%, and 5.0% oxygen), 
was greater than 200- fold during extreme hypoxia of <1.0% 
Figure 2. Evofosfamide- induced apoptosis in breast cancer cells in vitro. (A) Four breast cancer cell lines were seeded in 96- well plates at 1 × 104 cells 
per well and treated with evofosfamideat 50 μmol/L or coincubated with the broad specificity caspase inhibitor z- VAD- fmk (50 μmol/L). To exclude 
possible toxic effects of the inhibitor, cells were also treated with the inhibitor alone under normoxic and hypoxic (1% O2) conditions. Cell lysates 
were used to determine caspase- 3- like activity, using the caspase- 3- specific fluorogenic substrate, zDEVD- AFC, and cell viability was assessed via 
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after 24 h of treatment (Fig. 1B). Of interest, evofosfamide 
was also cytotoxic to MCF- 10A and MCF- 12A cells lines, 
normally regarded as normal epithelial cell lines of breast 
origin, when subjected under the same hypoxic conditions 
as the breast cancer cell lines, with IC50 values of 25 μmol/L 
and 2 μmol/L, respectively. In contrast normal human 
dermal fibroblasts and human primary mammary fibro-
blasts were relatively resistant to the cytotoxic activity of 
evofosfamide, with IC50 values of >50 μmol/L and 
40 μmol/L, respectively (Fig. 1C). Evofosfamide- mediated 
cytotoxicity in the breast cancer cell line MDA- MB- 231- 
TXSA under hypoxic conditions was associated with mor-
phological changes characteristic of apoptosis, including 
chromatin condensation, nuclear fragmentation as assessed 
by DAPI staining of nuclei (Fig. 1D).
Caspase activation is secondary in the 
apoptotic activity of evofosfamide
The observed decrease in cell viability with evofosfamide 
treatment under hypoxic conditions was associated with 
morphological changes characteristic of apoptosis, includ-
ing chromatin condensation and nuclear fragmentation, 
concomitant with an increase in caspase- 3 activation. 
However, coadministration with the pan- caspase inhibitor 
ZVAD- fmk failed to prevent the cytotoxic activity of evo-
fosfamide under hypoxic conditions, despite irreversibly 
inhibiting caspase- 3 activity (Fig. 2A) suggesting that the 
mechanisms of evofosfamide- mediated cytotoxicity are in 
part caspase independent. This is also supported by the 
observation that evofosfamide under hypoxic conditions 
was potently cytotoxic against MCF- 7 cells which are 
caspase- 3 deficient. [14] (Fig. 2B).
As a prelude to testing the anticancer efficacy of evo-
fosfamide in vivo, the MDA- MB- 231- TXSA cell line was 
chosen to further characterize the molecular determinants 
involved in apoptotic signaling, mediated by evofosfamide 
(Fig. 3A). Under hypoxic conditions (1% O2), evofosfamide 
treatment resulted in the prominent activation of the cas-
pase cascade with robust cleavage of the initiator caspase- 8 
followed by caspase- 9, and caspase- 3 and the concomitant 
processing of the mitochondrial proapoptotic Bcl- 2 family 
protein BID and the poly ADP- ribose polymerase (PARP) 
protein. While these changes were observed under hypoxic 
conditions, nonetheless this occurred only at the later time 
point of 48 h after the onset of cell death, indicating that 
Figure 3. Apoptotic signaling of evofosfamide as a single agent against MDA- MB- 231- TXSA cells. (A) MDA- MB- 231- TXSA- TGL cells were seeded at 
2 × 106 per T25 flask and were treated with evofosfamide at 50 μmol/L under normoxic (21% O2) and hypoxic (1% O2) conditions. Cells were then 
lysed and protein lysates were collected at 0, 6, 12, 24, and 48 h after treatment. Cell lysates were analyzed by polyacrylamide gel electrophoresis 
and transferred to PVDF membranes for immunodetection as described in Materials and Methods section. Evofosfamide treatment resulted in 
cleavage and prominent activation of the initiator caspase- 8 followed by caspase- 9, and caspase- 3 and the concomitant processing of BID and PARP 
protein, only at the later time point of 48 h, indicating that these changes were an effect rather than a cause of evofosfamide- induced apoptosis. 
cIAP1/2 levels were significantly reduced with evofosfamide treatment, under hypoxic conditions at the 24- and 48- h time points, whereas the levels 
of XIAP, BAX, and Bcl- 2 remained unchanged. (B) A robust reduction in PI3 kinase and phosphorylated AKT under hypoxic conditions after treatment 
with TH- 302 at 24 and 48 h. However, no significant changes in the levels of either phosphorylated or total MAPK were detected following treatment.
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these changes were an effect rather than a cause of 
evofosfamide- induced apoptosis. The levels of inhibitor of 
apoptosis proteins 1 and 2 (cIAP1/2) under hypoxic con-
ditions were significantly reduced with evofosfamide treat-
ment, which occurred at the 24- and 48- h time points, 
whereas the levels of XIAP, BAX, and Bcl- 2 remained 
unchanged. Due to the DNA alkalization caused by the 
Br- IPM component of evofosfamide, upregulation of p53 
was observed after 48 h of evofosfamide exposure in both 
normoxic and hypoxic conditions, leading to the upregula-
tion of the p53 target protein p21 after 48 h in normoxia 
and after 24 h in hypoxia. Additional signaling pathway 
analysis demonstrated a robust reduction in PI3 kinase 
and inhibition of phosphorylated AKT which was evident 
at 24 and 48 h after treatment with evofosfamide. However, 
no significant changes in the levels of either phosphoryl-
ated or total MAPK were detected following treatment.
Effect of evofosfamide and paclitaxel on the 
growth of orthotopic breast cancer 
xenografts
To investigate the anticancer efficacy of evofosfamide, 
paclitaxel ,and the combination of both against tumors 
growing in the orthotopic site, luciferase- tagged MDA- 
MB- 231- TXSA cells were injected directly into the mam-
mary fat pad of athymic female nude mice and treatment 
was initiated 7 days post cancer cell transplantation. These 
cells form aggressive, rapidly growing tumors when injected 
into the mammary fat pad, which can be accurately moni-
tored and quantified using noninvasive bioluminescence 
imaging [13]. Animals treated with vehicle showed an 
exponential increase of mean photon emission, associated 
with an increase in tumor burden, which was evident 
from day 7 onwards, reaching a maximum signal at day 
21, at which point animals had to be humanely killed. 
In contrast, all animals treated with evofosfamide or pacli-
taxel as single agents showed a significant reduction in 
tumor burden over the same period, whereas the com-
bination of both was highly effective which completely 
prevented tumor growth (Fig. 4A and B).
Effect of evofosfamide and paclitaxel 
against breast cancer- induced bone 
destruction
To evaluate the activity of evofosfamide against tumor 
growth in bone and its effects on cancer- induced bone 
Figure 4. Paclitaxel cooperates with evofosfamide to reduce MDA- MB- 231- TXSA- TGL orthotopic tumors in vivo. Mice were treated as described in 
Materials and Methods section and imaged weekly using the Xenogen IVIS 100 bioluminescence imaging system. (A) Representative whole body 
bioluminescent images of the mammary tumors of a single animal from each group and (B) the line graph, showing average tumor signal over time, 
expressed as mean photon counts per second during the course of the experiments are shown. Animals receiving treatment with evofosfamide and 
paclitaxel as single agents showed a significant delay in tumor growth. In addition, all mice receiving the combination of evofosfamide and paclitaxel 
showed a further delay of tumor growth when compared with each agent individually. Data shown in each case are the average bioluminescent 
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destruction, a xenogeneic tumor model was used, in which 
the MDA- MB- 231- TXSA- TGL cells were transplanted 
directly into the tibial marrow cavity of athymic mice. 
All vehicle- treated animals showed an exponential increase 
of mean photon emission associated with an increase in 
tumor burden, which was clearly evident from day 14 
onwards. By day 21, all animals developed large intratibial 
tumors that penetrated the cortical bone with the tumor 
mass, invading the surrounding soft tissue. For ethical 
reasons, all vehicle- treated animals were humanely killed 
on day 21 due to high tumor load and extensive oste-
olysis. In contrast, animals treated with evofosfamide or 
paclitaxel as single agents showed a significant delay in 
tumor growth and an overall reduction in tumor burden, 
whereas the combination of both agents demonstrated a 
far superior anticancer efficacy in bone (Fig. 5A and B).
At the end of the experiment, the tibiae of all mice 
were dissected and assessed, using high- resolution μCT 
Figure 5. Paclitaxel cooperates with evofosfamide for increased anticancer efficacy against the breast cancer line MDA- MB- 231- TXSA- TGL in vivo. 
MDA- MB- 231- TXSA- TGL cells were injected directly into the tibial marrow cavity of 4 week female athymic mice, allowed to establish for 7 days, as 
described in Materials and Methods section, mice were imaged weekly using the Xenogen IVIS 100 bioluminescence imaging system. (A) Representative 
whole- body bioluminescent images of a single mouse from each group during the course of the experiment are shown. (B) The line graph represents 
average tumor signal over time, measured as photon counts per second. Evofosfamide and paclitaxel as single agents reduced tumor growth, and in 
addition, the combination of both resulted in an even greater inhibition of tumor growth. (C) Quantitative assessment of total bone loss (%) 
comparing the tumor- bearing tibiae of each group to the contralateral tibiae and the qualitative 3- D micro CT images show the osteolytic nature of 
the MDA- MB- 231- TXSA- TGL cell line, which was reduced by paclitaxel and the combination of evofosfamide and paclitaxel. (D) Representative H&E- 
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for both quantitative and qualitative analysis of bone 
destruction (Fig. 5C). Extensive osteolysis was clearly evi-
dent in the vehicle- treated animals such that the net loss 
in bone volume (BV) was 94% in the left tumor- bearing 
tibiae when compared with the contralateral nontumor- 
bearing tibiae. While evofosfamide treatment reduced 
tumor burden, this did not translate to prevention of 
bone destruction such that the extent of osteolysis was 
not significantly different than the vehicle- treated group. 
In contrast, treatment with paclitaxel alone was significantly 
effective, decreasing bone loss to 21%. Combination therapy 
with evofosfamide and paclitaxel demonstrated additional 
protection of the bone architecture such that the net loss 
of BV was only 6%, although this improvement in bone 
protection by the combination therapy was not statistically 
significant when compared with paclitaxel alone. 
Histological examination of representative sections of the 
tibial sections show the MDA- MB- 231- TXSA- TGL tumor 
growing within the marrow cavity and in the surrounding 
tissue (Fig. 5D). Trabecular and cortical bone destruction 
was also evident, confirming the micro- CT data. Treatment 
with evofosfamide, paclitaxel, and the combination of both 
significantly reduced tumor size in the bone marrow con-
firming the bioluminescence data but did not completely 
eliminate breast cancer growth in bone.
Discussion
Tumor hypoxia is a major cause of treatment failure and 
poor outcome for a wide variety of malignancies [15]. 
Within most solid tumors, there are significant areas of 
hypoxia, which contain cancer cells that resist conventional 
anticancer chemotherapy and radiotherapy, and this pre-
disposes to tumor recurrence and metastasis [16, 17]. 
However, tumor hypoxia also offers treatment opportuni-
ties, exemplified by the development of highly active 
compounds that can specifically target tumor hypoxic 
zones. In this study, we assessed the hypoxia- selective 
cytotoxicity of evofosfamide against a panel of human 
breast cancer cell lines in vitro and investigated the anti-
cancer efficacy of evofosfamide as monotherapy and in 
combination with paclitaxel against breast cancer growing 
in the orthotopic site of the mammary gland and in the 
bone marrow using the aggressive and highly osteolytic 
MDA- MB- 231- TXSA breast cancer cells. Consistent with 
our previous published data [12], evofosfamide exhibited 
relatively minimal toxicity under normoxic conditions, 
whereas under increasing hypoxia evofosfamide treatment 
of a variety of human breast cancer cell lines dose 
 dependently decreased cell viability. Normal breast epi-
thelial cell lines MCF- 10A and MCF- 12A were also equally 
sensitive to evofosfamide under hypoxic conditions, which 
may be related to their proliferative capacity being similar 
to that of breast cancer cells. In contrast, primary dermal 
fibroblasts and normal mammary fibroblasts were relatively 
resistant to the cytotoxic activity of evofosfamide under 
the same conditions.
It is well established that the clinical management of 
breast cancer patients with different amplifications of 
markers such as ER+, PR+, and HER2 indicates different 
therapeutic strategies. Our results do not show any direct 
correlation between these markers and the cytotoxic activ-
ity of evofosfamide, suggesting perhaps a universally effec-
tive response. However, recent studies using a limited 
number of cell lines have shown a link between BRCA- 1, 
triple negativity of breast cancer and its response to evo-
fosfamide [18]. In this context, an extensive investigation 
using a large cohort of breast cancer cell lines and patient 
data will be required to delineate such differences in evo-
fosfamide therapeutic response.
While evofosfamide treatment induced changes char-
acteristic of apoptosis induction, coaddition with the 
broad- spectrum caspase inhibitor zVAD- fmk failed to 
protect breast cancer cells from the cytotoxic activity of 
evofosfamide under hypoxia, suggesting the involvement 
of caspase independent mechanism. This is also reflected 
by the activation of caspase- 3, caspase- 8, caspase- 9, cleav-
age of the Bcl- 2 family protein Bid, and the downregula-
tion of c- IAP1/2, which occurred 48 h post evofosfamide 
treatment, well after apoptosis induction and therefore, 
likely to represent events of the cell death process rather 
than a cause of evofosfamide- induced apoptosis. When 
evofosfamide is activated under hypoxia, the cytotoxic 
compound Br- IPM induces 1′3′- cross- linkage of DNA, 
which results in S139 phosphorylation of the histone H2AX 
leading to cell death [19]. This DNA damage is often 
associated with caspase independent mechanisms as previ-
ously reported [20] and is reflected by PARP cleavage 
leading to the upregulation of p53 followed by upregula-
tion of the p53 target protein and cell cycle regulating 
gene p21 as clearly observed here.
The therapeutic advantage of evofosfamide is expected 
to be greatest in combination with adjuvant cytotoxic 
chemotherapy. In this context, we tested the activity of 
evofosfamide in combination with paclitaxel, in a preclini-
cal model of breast cancer development and progression. 
We selected the breast cancer cell line MDA- MB- 231- 
TXSA, which we have shown in vitro to be the least 
sensitive to evofosfamide, such that any additive or syn-
ergistic activity will be readily detected. The antitumor 
effect of evofosfamide as a single agent in the mammary 
gland was most prominent from day 14 onwards when 
tumor size was approaching 1.0 cm3 which coincided with 
the presence of hypoxic tumor cores seen when tumors 
were excised from parallel untreated animals and assessed 
histologically at the same time (data not shown). While 
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Paclitaxel as a single agent was highly effective in reduc-
ing tumor burden, the combination of both completely 
prevented growth of the tumor within the mammary gland.
MDA- MB- 231- TXSA cells are highly osteolytic and when 
transplanted in to the tibial marrow cavity of mice lead 
to extensive bone destruction [13, 21]. This in vivo model 
mimics the late stages of bone metastasis and is ideally 
suited for monitoring the effects of drug treatment on 
breast cancer growth in the bone and also on cancer- induced 
bone destruction [13]. To date, the activity of evofosfamide 
against breast cancer growing in bone has not been reported. 
When breast cancer cells were injected intratibially, evo-
fosfamide treatment inhibited tumor growth in bone, leading 
to a significant reduction in the overall tumor burden. 
However, the reduction in tumor burden did not translate 
to a significant inhibition of osteolysis attesting to the 
aggressive osteolytic properties of these cells. In contrast, 
paclitaxel as a single agent was highly effective in reducing 
tumor load in bone while also protecting the bone from 
cancer- induced bone destruction. The combined treatment 
resulted in a reduction in tumor burden.
It is important to note that while hematological toxicity 
with evofosfamide treatment has been minimal, to date 
no data exist on the effects of evofosfamide or indeed 
any other HAP, on normal bone metabolism in the con-
text of osteoclasts, osteoblasts, or osteocyte survival and 
function. We have compared the micro architectural bone 
morphometric parameters of the contralateral nontumor 
injected tibiae from untreated and evofosfamide- treated 
animals and showed no obvious histological abnormalities 
on bone parameters including the number and viability 
of osteoclasts, or osteoblasts, per surface area (data not 
shown), whereas high- resolution micro- CT analysis dem-
onstrated no changes in micro architectural bone param-
eters, such as total or trabecular BV measurements with 
evofosfamide treatment (data not shown). These results 
are consistent with our previously published data in this 
context using a model of osteosarcoma [12].
Evofosfamide is currently being evaluated in numerous 
phase III and phase II clinical trials against a variety of 
cancer types either as monotherapy or in combination 
with conventional chemotherapy with promising results. 
Our data further support the clinical development of 
evofosfamide as a novel approach in the treatment of 
patients with breast cancer, especially those with existing 
bone metastases.
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